Novel Cancer Vaccine Prevents Melanoma From Returning in First for mRNA
The result is the first positive late-stage trial for an mRNA cancer vaccine and sent Moderna shares up more than 120%, the companies said.
- On Wednesday, Moderna and Merck announced their personalized mRNA vaccine intismeran combined with Keytruda met primary and secondary endpoints in a Phase 3 trial of 1,137 high-risk melanoma patients.
- Designed to target unique mutations in each patient's tumor, intismeran trains the immune system to identify and destroy remaining cancer cells as an adjuvant therapy administered after surgery.
- Shares of Moderna surged 93% on Wednesday after the vaccine-plus-Keytruda combination demonstrated superior efficacy in preventing melanoma recurrence and spread compared with Keytruda alone in the late-stage study.
- Merck and Moderna plan to present detailed trial results at an upcoming medical meeting and share findings with regulators, having already secured an expedited review pathway from the FDA and European Medicines Agency.
- Manufacturing each personalized dose takes six weeks, while companies explore this mRNA approach across nine additional Phase 2 and Phase 3 trials spanning melanoma, lung, bladder, kidney, pancreatic and gastric cancers.
368 Articles
368 Articles
Personalized Cancer Vaccine Shows Strong Results in Late-Stage Trial
How Does a Personalized Cancer Vaccine Work? Unlike a conventional vaccine that can be manufactured in the same form for millions of people, each dose of intismeran is made for one person based on the genetic characteristics of their cancer. “The idea behind the vaccine is to take the specific tumor that is growing inside one specific patient, use DNA sequencing to understand the unique bits and pieces of that particular cancer, and create a vac…
MRNA cancer drug shows success in curbing melanoma
US drugmakers Merck and Moderna on Wednesday said a personalized cancer treatment had shown success in reducing the recurrence of melanoma tumors in a late-stage trial hailed by experts as a “breakthrough.”The drug, called “intismeran autogene,” is based on the same messenger RNA (mRNA) technology b
Next-Gen mRNA Vaccines Are Revolutionizing Medicine. Will MAGA/MAHA Choose to Be Left Behind?
This week, news arrived of the latest potential breakthrough in medical science related to the development of mRNA vaccines: Pharmaceutical companies Moderna and Merck announced results from a late-stage trial of 1,137 people with high-risk melanoma (skin cancer) who had undergone surgery to have their cancer removed, and then received a novel, personalized cancer vaccine called intismeran (mRNA-4157) along with standard immunotherapy drugs like…
PBS NewsHour
BizTocModerna shares surge after it says experimental mRNA cancer treatment passed key test
Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based on unique mutations within their tumors.
Coverage Details
Bias Distribution
- 51% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
